Mirum Pharmaceuticals shares are trading higher after the company announced that the FDA approved LIVMARLI oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $45 to $58.
Benzinga Newsdesk - Mar 14, 2024, 7:54AM